INTRODUCTION
============

Methamphetamine (METH) is a psychomotor stimulant with high liability for abuse, and METH abuse has become a very serious social problem in Japan \[[@R1]\]. Chronic METH abusers have been shown to have persistent dopaminergic deficits \[[@R2],[@R3]\]. In animals, amphetamine elevates extracellular dopamine levels in the mesolimbic circuits \[[@R4],[@R5]\]. There is growing evidence that serotonergic systems modulate dopaminergic neurotransmission. For example, the mesocorticolimbic dopamine system is under inhibitory control by the serotonin system, which exerts its actions *via* serotonin receptor subtypes \[[@R6],[@R7]\].

Acute and chronic administration of METH markedly decreases the activity of tryptophan hydroxylase (TPH) \[[@R8],[@R9]\], the rate-limiting enzyme in the biosynthesis of serotonin \[[@R10]\]. TPH2 (or neuronal TPH) was identified as a second isoform of TPH in 2003 \[[@R11],[@R12]\]. In contrast to TPH1, which is expressed predominantly in the pineal gland and the periphery, TPH2 mRNA is expressed in the raphe nuclei \[[@R11]\]. Since the identification of TPH2, there have been numerous association analyses between *TPH2* gene variants and psychiatric diseases. For example, associations have been observed between *TPH2* variants and bipolar disorder \[[@R13]-[@R18]\], suicidal behavior in major depression \[[@R19]-[@R21]\], the response to selective serotonin reuptake inhibitors (fluoxetine and/or citalopram) \[[@R22],[@R23]\] and emotional regulation in healthy subjects \[[@R24]-[@R28]\]. These reports indicate that polymorphic variants in the *TPH2* gene may have a role in the pathophysiology of a wide range of psychiatric disorders and emotional regulation. A recent study of heroin addiction also showed an association with *TPH2* variants in Hispanics and African-Americans \[[@R29]\].

The purpose of this study was (1) to identify novel sequence variations in all coding exons as well as exon-intron boundaries of the *TPH2* gene in Japanese, and (2) to investigate whether these polymorphisms and/or haplotypes were associated with METH dependence/psychosis.

MATERIALS AND METHODS
=====================

Subjects
--------

One-hundred sixty-two unrelated patients with METH dependence/psychosis (130 males and 32 females; mean age 37.4±12.0 years) meeting ICD-10-DCR criteria (F15.2 and F15.5) were used as case subjects; they were outpatients or inpatients of psychiatric hospitals. The 243 control subjects (168 males and 75 females; mean age 35.4±11.5 years) were mostly medical staff members who had neither personal nor familial history of drug dependence or psychotic disorders, as verified by a clinical interview. All subjects were Japanese, born and living in the northern Kyushu, Setouchi, Chukyo, Tokai, and Kanto regions. This study was approved by the ethical committees of each institute of the Japanese Genetics Initiative for Drug Abuse (JGIDA), and all subjects provided written informed consent for the use of their DNA samples for this research \[[@R30]\]. After informed consent was obtained, blood samples were drawn and genomic DNA was extracted by the phenol/chloroform method.

Defining Variants of the *TPH2* Gene
------------------------------------

Initially, 16 METH dependent/psychotic patient samples were used to identify nucleotide variants within the *TPH2* gene (GenBank accession no. AC090109). Exons 1 to 11 and exon-intron boundaries were amplified by polymerase chain reaction (PCR) using a thermal cycler (Astec, Fukuoka, Japan), and the products were sequenced in both directions using BigDye terminators (Applied Biosystems, Foster City, CA) by an ABI Genetic analyzer 3100 (Applied Biosystems).

Genotyping of each polymorphism except in exon 11 was performed by PCR amplification using the relevant primers listed in Table **[1](#T1){ref-type="table"}** followed by sequencing using the same primers in both directions. Genotyping of polymorphisms in exon 11 was performed by PCR amplification using 9F and 11R primers followed by sequencing using 10F, 11F, and 11R primers.

Patient Subgroups
-----------------

For the clinical category analysis, the patients were divided into two subgroups by three different clinical features. (A) Latency of psychosis from first METH intake: less than 3 years or more than 3 years. The course of METH psychosis varied among patients, with some patients showing psychosis sooner after the first METH intake, as previously reported \[[@R30],[@R31]\]. Because the median latency was three years, this time point was used as the cutoff in defining the two groups. (B) Duration of psychosis after the last METH intake: transient (\<1 month) or prolonged ( ≧1 month). Some patients showed continuous psychotic symptoms even after METH discontinuation, as previously reported \[[@R30],[@R31]\]. Patients with the transient type showed a reduction of psychotic symptoms within one month after the discontinuation of METH consumption and the beginning of treatment with neuroleptics. Patients with the prolonged type showed a psychotic symptoms continued for more than one month even after the discontinuation of METH consumption and the beginning of neuroleptic treatment. (C) Spontaneous relapse: present or not. It has been well documented that once METH psychosis has developed, patients in the remission phase are liable to spontaneous relapse without reconsumption \[[@R30],[@R31]\].

Statistical Analysis
--------------------

The Hardy-Weinberg equilibrium of genotypic frequencies in each SNP was tested by the chi-square test. The level of statistical significance was set at α= 0.05. The allelic and genotypic frequencies of patients and control groups were compared using the chi-square test. Locus by locus linkage disequilibrium (LD) was evaluated by D' and r^2^, which were calculated by the haplotype frequencies using the appropriate formula in the Excel program. A global test of differentiation among samples based on haplotype frequencies was performed using the Arlequin program available from <http://anthropologie.unige.ch/arlequin> \[[@R32]\].

RESULTS
=======

To identify polymorphisms in the *TPH2* gene, all coding exons (1 to 11) and exon-intron boundaries were analyzed using genomic DNA from 16 Japanese METH-dependent/psychotic subjects. Ten single nucleotide polymorphisms (SNPs) and two insertion / deletion polymorphisms were identified. One polymorphism, Exon11+(C3) 500(C2), was novel (Table **[2](#T2){ref-type="table"}**). Two SNPs, rs7305115 (Exon7+A131G) and rs4290270 (Exon9+A57T), were synonymous mutations and Eon2+C18A was a non-synonymous mutation. Three linkage disequilibrium (LD) regions were found, rs11178998 (Exon1-A42G) to rs41265611 (IVS1+60(I/D)), rs11179003 (IVS4+C4821T) to rs10879348 (IVS6+G144A), and rs4760816 (IVS6+C6106T) to rs7305115 (Exon7+A131G), in the sense that all genotypic patterns in all 16 samples analyzed were the same. Each one of the SNPs was chosen and a total of nine SNPs were genotyped for further analysis. LD mapping was analyzed by using SNPs having minor allele frequencies of over 10% in both samples (Table **[4](#T4){ref-type="table"}**). LD was observed from rs17110566 (IVS6+G152A) to rs17110747 (Exon11+G654A) and from rs4290270 (Exon9+A57T) to rs41317114 (IVS11+G128C) (Fig. **[1](#F1){ref-type="fig"}** and Table **[3](#T3){ref-type="table"}**).

Association analyses were performed on these nine polymorphic positions using 162 METH dependent/psychotic patients and 243 controls. Genotypic frequencies in these SNPs were within the Hardy-Weinberg expectations. No significant differences were found in the allelic or genotypic frequencies of these SNPs between the METH dependent/psychotic patients and the controls (Table **[4](#T4){ref-type="table"}**). Since the minor allele frequency of the Exon11+(C3)500(C2) SNP was less than 1% in controls, this SNP was excluded from the haplotype analysis. No significant difference (P=0.448) was observed in a differentiation test between all pairs of samples based on haplotype frequencies by the Arlequin program.

Subcategory analyses were conducted on the clinical parameters (latency of psychosis, prognosis of psychosis, and spontaneous relapse). SNPs having minor allele frequencies of over 10% in both samples were used for this analysis: rs17110566 (IVS6+G152A), rs4760816 (IVS6+C6106T), rs4290270 (Exon9+A57T), rs17110747 (Exon11+G654A), and IVS11+G129C. No significant associations with clinical parameters were observed (Table **[5](#T5){ref-type="table"}**).

DISCUSSION
==========

We analyzed the *TPH2* gene polymorphisms in a Japanese population and found ten SNPs and two insertion/deletion variants, among which one variant was novel. However, we failed to identify any variants or haplotypes in the *TPH2* gene examined in this study which were associated with METH dependence/psychosis.

Exon2+C18A is a nonsynonymous SNP and the corresponding amino acid is changed from Ser to Tyr at peptide position 41 (S41Y). This SNP was reported as C2755A by Lin and colleagues in a Han Chinese population \[[@R14]\]. They transfected plasmids containing full-lengthTPH2 protein--encoding sequences with two alternative alleles into SH-SY5Y cells and found that the amount of serotonin in SH-SY5Y cells expressing the 41Y allele was about 36% lower than in cells expressing the 41S allele. Despite the strong scientific rationale for studying polymorphisms in the *TPH2* gene in METH dependence/psychosis, we could not identify any variants or haplotypes associated with the phenotype. These results were comparable to those for cocaine use. Both cocaine and METH increase extracellular dopamine in the brain, and increased dopamine in the nucleus accumbens is thought to underlie the reinforcing effects of drugs of abuse \[[@R5],[@R33]\]. The association of cocaine dependence in subjects of African descent with TPH2 SNPs was analyzed by Dahl and colleagues, but they failed to identify any SNPs that were associated with the cocaine-dependent phenotype \[[@R34]\]. The disparity between these results and the previously reported results for heroin addiction \[[@R29]\] suggest that the *TPH2* gene has little effect in psychostimulants with the characteristics of indirect dopaminergic agonists.

Our results indicate that the *TPH2* gene variations may not be vulnerability factors in METH dependence/psychosis, and indeed that they are likely to make a small or no contribution to the development of METH dependence/psychosis.
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###### 

Primers Used in this Study

  Exon          Forward   Reverse                                 
  ------------- --------- --------------------------------- ----- ---------------------------------
  Exon 1        1F        CCT TAT GTA TTG TTC TCC ACC ACC   1R    GTT GAG CAC GCA GTG ATT GGC ACA
  Exon 2        2F        CCA CTA GAT GAT GTC TTA GAC CAT   2R    CTG ACC TCC TAA CCT GGC AAT AGT
  Exon 3,4      3F        GTA CTT GGC ACC TTG CTT AAG ATG   3R    TGG AAG TCT GCT CTC AGT TAT GGG
  Exon 5        4F        GCT CAA CTA AGC CAT TCT GCT TAC   4R    GTA GCA CTT GGC ATG TGG CTC ACA
  Exon 6        5F        GAT CCT TTC AGA CGC TCA TGT GCT   5R    CAT ACT CAT GTA GCC CAG CAC AGC
  Exon 7        6F        GTG CGG TAA GCA TCA CTT TCG ATT   6R    CAG ATG AGG AGT CTG ATC CTT CAG
  Exon 8        7F        GAA GTC CCA GCA TTG ATG AAC TGT   7R    GGC TAA GCT GAG TAA TTC TGA CAG
  Exon 9        8F        CAG GAA GCG TAA GAC TCT TAG TAG   8R    GTC AGT AGG ATC ACT GCT AGC TCA
  Exon 10, 11   9F        CCT GCA CAC AGG AGA GTT CCA TAT   9R    CAT GCT GGC AAC AAC ATA GTT CCA
                10F       CAA TCC CTA CAC ACA GAG TAT TGA   10R   CAT TCC AAC TGC TGT GTT ACC TCA
                11F       GAT CTA AGC CTT TCC TCT GTG TTC   11R   GAC ACA GAA ACA CAT GCA AGC ACT

###### 

*TPH2* Gene Variants Found in the Japanese Population

  Position[1)](#T2FN1){ref-type="fn"}   Location   rs Number[2)](#T2FN2){ref-type="fn"}   SNP Name                                Variation   Function
  ------------------------------------- ---------- -------------------------------------- --------------------------------------- ----------- --------------------------
  30029                                 5\' side   rs11178998                             Exon1-A42G                              A/G         
  30241                                 Intron 1   rs41265611                             IVS1+60(I/D)                            TCT/del     
  32694                                 Exon 2                                            Exon2+C18A[3)](#T2FN3){ref-type="fn"}   C/A         nonsynonymous (Ser41Tyr)
  40601                                 Intron 4   rs11179003                             IVS4+C4821T                             C/T         
  63953                                 Intron 6   rs10879348                             IVS6+G144A                              G/A         
  63961                                 Intron 6   rs17110566                             IVS6+G152A                              G/A         
  69915                                 Intron 6   rs4760816                              IVS6+C6106T                             C/T         
  70176                                 Exon 7     rs7305115                              Exon7+A131G                             A/G         synonymous (Pro312Pro)
  113549                                Exon 9     rs4290270                              Exon9+A57T                              A/T         synonymous (Ala375Ala)
  123114                                Exon 11                                           Exon11+(C3)500(C2)                      C3/C2       
  123268                                Exon 11    rs17110747                             Exon11+G654A                            G/A         
  123663                                3\' side   rs41317114                             IVS11+G128C                             G/C         

Position: nucleotide position number in the NCBI nucleotide database under accession number AC090109.

rs number: NCBI SNP database.

This SNP was reported as C2755A \[[@R14]\].

###### 

Linkage Disequilibrium Mapping of the *TPH2* Gene

  --
  --

D\' and r^2^ values for Control samples are shown in the upper right and lower left, respectively.

###### 

Genotypic and Allelic Distribution of the *TPH2* gene SNPs in the METH Dependent/Psychotic Patients and the Control Groups

  SNP                         Group        Genotype (%)   P          Allele (%)   P                               
  --------------------------- ------------ -------------- ---------- ------------ ----------- ----------- ------- --
  rs11178998 (Exon1-A42G)                  A/A            A/G        G/G                      A           G       
  METH                        130 (80%)    29 (18%)       3 (2%)     0.102        289 (89%)   35 (11%)    0.617   
  Control                     197 (81%)    46 (19%)       0 (0%)     440 (91%)    46 (9%)                         
  Exon2+C18A                               C/C            C/A        A/A                      C           A       
  METH                        146 (90%)    16 (10%)       0 (0%)     0.914        308 (95%)   16 (5%)     0.807   
  Control                     222 (91%)    21 (9%)        0 (0%)     465 (96%)    21 (4%)                         
  rs10879348 (IVS6+G144A)                  G/G            G/A        A/A                      G           A       
  METH                        136 (84%)    26 (16%)       0 (0%)     0.975        298 (92%)   26 (8%)     0.920   
  Control                     206 (85%)    37 (15%)       0 (0%)     449 (92%)    37 (8%)                         
  rs17110566 (IVS6+G152A)                  G/G            G/A        A/A                      G           A       
  METH                        123 (76%)    35 (22%)       4 (2%)     0.552        281 (87%)   43 (13%)    0.406   
  Control                     173 (71%)    64 (26%)       6 (2%)     410 (84%)    76 (16%)                        
  rs4760816 (IVS6+C6106T)                  C/C            C/T        T/T                      C           T       
  METH                        28 (17%)     85 (52%)       49 (30%)   0.314        141 (44%)   183 (56%)   0.200   
  Control                     57 (23%)     121 (50%)      65 (27%)   235 (48%)    251 (52%)                       
  rs4290270 (Exon9+A57T)                   A/A            A/T        T/T                      A           T       
  METH                        29 (18%)     80 (49%)       53 (33%)   0.840        138 (43%)   186 (57%)   0.777   
  Control                     49 (20%)     115 (47%)      79 (33%)   213 (44%)    273 (56%)                       
  Exon11+(C3)500(C2)                       C3/C3          C3/C2      C2/C2                    C3          C2      
  METH                        159 (98%)    3 (2%)         0 (0%)     0.357        321 (99%)   3 (1%)      0.357   
  Control                     242 (100%)   1 (0%)         0 (0%)     485 (100%)   1 (0%)                          
  rs17110747 (Exon11+G654A)                G/G            G/A        A/A                      G           A       
  METH                        92 (57%)     63 (39%)       7 (4%)     0.956        247 (76%)   77 (24%)    0.888   
  Control                     136 (56%)    95 (39%)       12 (5%)    367 (76%)    119 (24%)                       
  rs41317114 (IVS11+G128C)                 G/G            G/C        C/C                      G           C       
  METH                        119 (73%)    38 (23%)       5 (3%)     0.719        276 (85%)   48 (15%)    0.462   
  Control                     187 (77%)    50 (21%)       6 (2%)     424 (87%)    62 (13%)                        

###### 

Genotypic Distribution of the *TPH2* Gene SNPs in Clinically Subcategorized METH Subjects

  SNP                         Groups                  Subgroup    N     Genotype   P                       
  --------------------------- ----------------------- ----------- ----- ---------- ------- ------- ------- --
  rs17110566 (IVS6+G152A)                                                          G       G/A     A       
  Control                                                         243   173        64      6               
  METH                        Latency of Psychosis    \<3 years   64    53         10      1       0.172   
  ≧3 years                    67                      47          18    2          0.966                   
  Prognosis of Psychosis      Transient (\<1 month)   87          67    17         3       0.421           
  Prolonged (≧1 month)        52                      38          13    1          0.951                   
  Spontaneous Relapse         Not present             101         78    21         2       0.517           
  Present                     56                      42          12    2          0.694                   
  rs4760816 (IVS6+C6106T)                                                          C       C/T     T       
  Control                                                         243   57         121     65              
  METH                        Latency of Psychosis    \<3 years   64    13         35      16      0.771   
  ≧3 years                    67                      9           35    23         0.165                   
  Prognosis of Psychosis      Transient (\<1 month)   87          15    39         33      0.125           
  Prolonged (≧1 month)        52                      7           34    11         0.107                   
  Spontaneous Relapse         Not present             101         19    51         31      0.577           
  Present                     56                      8           30    18         0.306                   
  rs4290270 (Exon9+A57T)                                                           A       A/T     T       
  Control                                                         243   49         115     79              
  METH                        Latency of Psychosis    \<3 years   64    8          35      21      0.338   
  ≧3 years                    67                      13          32    22         0.990                   
  Prognosis of Psychosis      Transient (\<1 month)   87          16    37         34      0.541           
  Prolonged (≧1 month)        52                      6           34    12         0.058                   
  Spontaneous Relapse         Not present             101         17    52         32      0.712           
  Present                     56                      10          27    19         0.923                   
  rs17110747 (Exon11+G654A)                                                        G       G/A     A       
  Control                                                         243   136        95      12              
  METH                        Latency of Psychosis    \<3 years   64    35         28      1       0.438   
  ≧3 years                    67                      37          26    4          0.947                   
  Prognosis of Psychosis      Transient (\<1 month)   87          52    31         4       0.827           
  Prolonged (≧1 month)        52                      26          25    1          0.366                   
  Spontaneous Relapse         Not present             101         57    41         3       0.712           
  Present                     56                      32          21    3          0.970                   
  rs41317114 (IVS11+G128C)                                                         G       G/C     C       
  Control                                                         243   187        50      6               
  METH                        Latency of Psychosis    \<3 years   64    49         15      0       0.411   
  ≧3 years                    67                      48          16    3          0.552                   
  Prognosis of Psychosis      Transient (\<1 month)   87          65    19         3       0.852           
  Prolonged (≧1 month)        52                      38          13    1          0.767                   
  Spontaneous Relapse         Not present             101         77    21         3       0.966           
  Present                     56                      38          17    1          0.282                   

N: Number of samples.

P: Significance values between the METH subjects and the controls.

[^1]: Current address: Research Unit of Genome New Drugs, School of Pharmacy, Nihon University, Chiba 274-8555, Japan
